$1.6B
Gene therapy total deal value at Phase 2 in 2026
Gene therapy deals are structured to reflect the curative potential of single-administration treatments. With upfront payments of $253M, these deals include significant regulatory and commercial milestones tied to durable efficacy data and market access.
Based on analysis of 600+ biopharma licensing deals from 2020-2026
Get deal intelligence in your inbox
Weekly benchmarks, market signals, and deal analysis from 1,900+ transactions.
No spam. Unsubscribe anytime.
Benchmarks powered by 1,900+ real biopharma licensing deals
Try the Deal Calculator →